Given their usual occurrence outside the context of IDH1/2 mutations, the oncogenic role of TP53 mutations in gliosarcoma and primary GBM may be different than in IDH-mutant lower grade glioma and secondary glioblastoma. The gene discussed is IDH1; the disease is central nervous system cancer.